GSK's asthma drug Nucala wins FDA's approval to treat 'smoker's lung'

 The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic lung disease commonly known as "smoker's lung", the company said on Thursday.

The approval expands the use of the drug, Nucala, as an add-on treatment for patients with chronic obstructive pulmonary disease, with an eosinophilic phenotype.

Sanofi and Regeneron's blockbuster drug Dupixent and Verona Pharma's inhaled therapy Ohtuvayre are also approved for the condition, which affects the lungs, causing restricted airflow and breathing problems.

GSK's Nucala is a monoclonal antibody that inhibits interleukin-5, which helps regulate eosinophils, a type of white blood cell that causes inflammation in the lungs when overproduced.

https://www.marketscreener.com/quote/stock/GSK-PLC-9590199/news/GSK-s-asthma-drug-Nucala-wins-FDA-s-approval-to-treat-smoker-s-lung-50042399/